GHのニュース
Guardant Health announces new data to be presented at 2023 Digestive Disease Week showcasing the potential of its blood-based technology to detect colorectal cancer 2023/04/21 12:05:00 Business Wire
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, is pleased to announce that it will present data from two studies highlighting the performance of its blood-based screening technology to detect early-stage colorectal cancer (CRC), including the acceptance of the ECLIPSE study as a late-breaking abstract, at Digestive Disease Week (DDW) taking place in Chicago, Illinois on May 6-9, 2023. “Despite multiple screening modalities for color
Guardant Health: On Hold For Now (NASDAQ:GH) 2023/04/20 23:57:09 Seeking Alpha
Shares of liquid biopsy genetic profiling test developer Guardant Health, Inc. have cratered 85% since achieving their all-time high. Click here for our GH review.
Guardant immunotherapy response test covered by Medicare 2023/04/18 12:59:59 Seeking Alpha
Medicare has agreed to cover Guardant Health (GH) Guardant360 Response test, which is used to assess a cancer patients response to immune checkpoint inhibitors.
Guardant Health Receives Medicare Coverage for Guardant360 Response™ to Monitor Cancer Patient Response to Immunotherapy 2023/04/18 12:05:00 Business Wire
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health receives Medicare coverage for Guardant360 Response™ to monitor cancer patient response to immunotherapy
Guardant Health Receives Medicare Coverage for Guardant360 Response to Monitor Cancer Patient Response to Immunotherapy 2023/04/18 12:05:00 Wallstreet:Online
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that Palmetto GBA, a Medicare administrative contractor for the Molecular Diagnostics Services program (MolDX), has conveyed coverage for the Guardant360 Response test. Guardant360 Response is the first blood-only test that enables doctors to track molecular response through changes in circulating tumor DNA
Hedge Fund and Insider Trading News: Elliott Management, Accendo Capital, Haidar Capital Management, Odey Asset Management, Guardant Health Inc (GH), New Mountain Finance Corp. (NMFC), and More 2023/03/16 17:57:51 Insider Monkey
Elliott Boosts Stake in Triple Flag to 67% (Reuters) Elliott Investment Management on Thursday raised its stake in gold-focused streaming and royalty firm Triple Flag Precious Metals Corp to 67% from 64.7%. The hedge fund acquired 4.7 million shares in Triple Flag at C$16.50 per share. Triple Flag provides upfront financing to miners in exchange […]
Guardant Health Earnings Perspective: Return On Capital Employed 2023/03/16 14:46:37 Benzinga
According to Benzinga Pro data, during Q4, Guardant Health (NASDAQ: GH ) posted sales of $126.89 million. Earnings were up 13.62%, but Guardant Health still reported an overall loss of $139.93 million. Guardant Health collected $117.40 million in revenue during Q3, but reported earnings showed a $161.99 million loss. What Is Return On Capital Employed? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a company … Full story available on Benzinga.com
Guardant Health Submits Colorectal Cancer Screening Test to FDA for Premarket Approval 2023/03/10 15:29:17 GenomeWeb
The firm''s application is supported by data from the ECLIPSE study, which compared results of the Shield test to colonoscopy findings in 20,000 individuals.
Guardant seeks FDA approval of colorectal cancer detection blood test 2023/03/10 13:25:20 Seeking Alpha
Guardant Health (GH) submitted the final module of a premarket approval ((PMA)) application to the U.S
Guardant Health submits premarket approval application to the U.S. Food and Drug Administration for Shield blood test 2023/03/10 13:05:00 Wallstreet:Online
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that it has submitted to the U.S. Food and Drug Administration (FDA) the final module of its premarket approval (PMA) application for Shield, Guardant Health’s blood test to screen for colorectal cancer (CRC). The submission is comprised of data from the company’s positive ECLIPSE study, an over 20,000
Guardant Health: More Catalysts To Power Leaping Growth 2023/02/10 16:55:02 Seeking Alpha
Despite recent data hiccups for Guardant Health, you can expect much more upsides to GH stock. Click here for our take on GH and its prospects.
Guardant wins UnitedHealthcare coverage for cancer diagnostic test 2023/02/08 13:58:43 Seeking Alpha
Guardant Health (GH) announced Wednesday that UnitedHealth (UNH), has decided to cover its Guardant360 CDx liquid biopsy test for all of its commercial policies. Read the full story here.
Guardant Health receives coverage from UnitedHealthcare for Guardant360 CDx blood test as companion diagnostic in advanced lung and breast cancer 2023/02/08 13:05:00 Wallstreet:Online
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that UnitedHealthcare (UHC) now covers the Guardant360 CDx liquid biopsy test for patients enrolled in its commercial policies for all FDA-approved companion diagnostic indications. The test is used by oncologists as a companion diagnostic to assess if patients are eligible for a targeted therapy for advanced
Guardant Health receives coverage from UnitedHealthcare for Guardant360® CDx blood test as companion diagnostic in advanced lung and breast cancer 2023/02/08 13:05:00 Business Wire
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that UnitedHealthcare (UHC) now covers the Guardant360® CDx liquid biopsy test for patients enrolled in its commercial policies for all FDA-approved companion diagnostic indications. The test is used by oncologists as a companion diagnostic to assess if patients are eligible for a targeted therapy for advanced or metastatic breast or non-small cell lung cancer (NSCLC). T
Can you now get a good deal on Guardant Health Inc.’s shares? 2023/02/08 12:54:00 US Post News
Guardant Health Inc. (NASDAQ:GH) marked $28.56 per share on Tuesday, down from a previous closing price of $29.56. While Guardant Health Inc. has underperformed by -3.38%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, GH fell by -60.88%, with highs and lows ranging from $78.34 to […]